\n <\/p>\n
Revealed on Jun 10, 2026<\/p>\n
<\/p>\n
\n <\/p><\/blockquote>\n
Convention Name At the moment at 4:30 p.m. ET<\/em><\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
\n <\/ul>\n
<\/p>\n
\n <\/p><\/blockquote>\n
<\/p>\n
<\/p>\n
Contact us for more information
\n <\/p><\/div>\n
Revealed on Jun 10, 2026
Share
Paid information dissemination
JOIN OUR FREE TELEGRAM SERVER TODAY Actual-time inventory alerts throughout Mining, Crypto, AI\/Tech, Protection & Biotech channels
Be a part of Free
Investorideas.com (www.investorideas.com newswire) a […]<\/p>\n","protected":false},"author":1,"featured_media":10594,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.investorideas.com\/CO\/AEMD\/news\/2026\/images\/061026-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[41],"tags":[2500,4949,2902,3421,5531,73,236,4950,2765,265,1417,211],"class_list":["post-10592","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investment","tag-advances","tag-aemd","tag-australian","tag-cohort","tag-dosing","tag-final","tag-fiscal","tag-oncology","tag-reports","tag-results","tag-study","tag-year"],"yoast_head":"\n
\n
\n Share
\n <\/a>
\n<\/section><\/div>\n
\n
<\/p>\n
\n Paid information dissemination
\n <\/p>\n
\n
\n
\n
<\/p>\nJOIN OUR FREE TELEGRAM SERVER<\/span> TODAY<\/h3>\n
\n Be a part of Free
\n <\/a>\n <\/div>\n<\/div>\n
\n
<\/p>\n
\n ![\"Aethlon](\"https:\/\/www.investorideas.com\/CO\/AEMD\/news\/2026\/images\/061026-1.jpg\")
\n <\/figure>\n
\n
<\/p>\n
\n Investorideas.com (www.investorideas.com newswire<\/a>) a trusted funding platform for retail buyers reviews breaking
\n Medical Tech Inventory information for
\n Aethlon Medical, Inc.<\/a>
\n (Nasdaq: AEMD<\/a>), a clinical-stage medical therapeutic firm targeted on creating
\n merchandise to deal with most cancers and life-threatening viral infections for
\n which there is no such thing as a therapy.
\n <\/p>\n
\n
<\/p>\n
\n Business commentary: SentimenTrader notes that healthcare has
\n quietly demonstrated sturdy defensive qualities, outperforming
\n the S&P 500 on 85% of the times the broader market posted
\n losses of 1% or extra over the previous yr. This resilience
\n underscores the sector’s potential as a dependable performer
\n throughout market downturns.<\/strong><\/em>
\n <\/p>\n
\n
<\/p>\n
\n Aethlon Medical, Inc.<\/a>
\n (Nasdaq: AEMD<\/a>) immediately reported monetary outcomes for its fiscal yr ended March
\n 31, 2026, and supplied an replace on current developments.
\n <\/p>\n
\n
<\/p>\n
\n Abstract<\/strong> – Australian oncology research advances
\n into Cohort 3 as enrollment continues<\/em>
\n <\/p>\n
\n
<\/p>\n
\n Entered the third and closing dosing cohort of the Australian oncology
\n research, expanded the Hemopurifier mental property portfolio, and
\n maintained a concentrate on managing working bills.
\n <\/p>\n
\n
<\/p>\n
\n
<\/p>\nKey Highlights<\/h2>\n
\n
<\/p>\n
<\/p>\n
\n
<\/p>\n
\n “Fiscal 2026 was a yr of significant execution for Aethlon as we
\n superior our Australian oncology research by way of the primary two cohorts
\n and not too long ago initiated Cohort 3.
\n Development into the ultimate cohort represents an vital
\n medical milestone as we work towards producing knowledge that will assist
\n outline the optimum therapy routine and information future improvement
\n selections.<\/strong>
\n We additionally strengthened the Hemopurifier platform by way of growth of
\n our mental property portfolio and development of preclinical
\n analysis supporting potential functions past oncology.
\n Mixed with our continued concentrate on managing working bills,
\n these achievements place us to pursue a number of value-creating
\n alternatives throughout our medical and analysis packages.<\/strong>” mentioned James Frakes, Chief Government Officer and Chief Monetary
\n Officer of Aethlon Medical.
\n <\/p>\n
\n
<\/p>\nScientific Replace<\/h2>\n
\n
<\/p>\nScientific Progress in Most cancers Trial<\/h3>\n
\n
<\/p>\n
\n Enrollment and therapy of contributors in Cohort 2 of the
\n Australian oncology trial have been accomplished. An impartial Information
\n Security Monitoring Board reviewed the info, recognized no security
\n issues based mostly on its evaluation of accessible knowledge, and beneficial
\n advancing to the third and closing cohort. Screening is actively
\n underway on the three investigative websites for this closing cohort the place
\n 3-6 contributors might be handled with 3 Hemopurifier periods throughout a
\n 1-week interval. The primary participant in Cohort 3 of the research has been
\n enrolled and acquired three Hemopurifier remedies with none gadget
\n deficiencies or instant problems and is now within the follow-up
\n interval. Profitable enrollment and therapy of the primary participant in
\n Cohort 3 maintains the research’s medical momentum and strikes the Firm
\n nearer to finishing enrollment and producing knowledge from all deliberate
\n dosing regimens.
\n <\/p>\n
\n
<\/p>\n
\n Serial Extracellular Vesicle and T cell measurements on contributors
\n in cohort 2 have been measured by the central lab on the College of
\n Sydney. Formal statistical analyses evaluating the results of the three
\n totally different Hemopurifier dosing regimens on these parameters might be
\n carried out by a CRO on the completion of the trial. This nine-to-18
\n affected person research is designed to judge the security and feasibility of the
\n Hemopurifier remedies and decide the suitable dosing in
\n contributors with stable tumors whose illness is secure or progressing
\n whereas on a therapy that features the anti-PD-1 brokers, Keytruda(R)
\n or Opdivo(R).
\n <\/p>\n
\n
<\/p>\nDifferent Current Developments<\/h3>\n
\n
<\/p>\n
\n Throughout fiscal 2026, we strengthened our mental property
\n portfolio by way of the issuance of patents in each the USA
\n and Europe protecting potential functions of the Hemopurifier for
\n coronavirus-related situations, together with lengthy COVID and different
\n post-infection problems. These patents lengthen safety for
\n sure functions of the Hemopurifier into the 2040s and additional
\n strengthen the Firm’s mental property place surrounding the
\n Hemopurifier.
\n <\/p>\n
\n
<\/p>\n
\n As well as, we superior our preclinical extracellular vesicle (EV)
\n analysis actions, together with research evaluating elimination of EVs in
\n plasma samples from sufferers with rheumatoid arthritis and persistent
\n kidney illness. These efforts assist the Firm’s ongoing analysis
\n of the Hemopurifier’s potential functions throughout a number of illness
\n classes and
\n could create future alternatives to increase the platform into giant
\n markets characterised by vital unmet medical want.<\/strong>
\n <\/p>\n
\n
<\/p>\n
\n Individually, we continued our analysis of Hemopurifier compatibility
\n with a simplified blood therapy system being developed by Stavro
\n Medical. Preliminary testing assessing circulation charges and switch of fluid
\n by way of the Hemopurifier has been accomplished, and future research
\n evaluating elimination of surrogate markers for extracellular vesicles by
\n the Hemopurifier utilizing the system are into account. We consider
\n this method may increase potential therapy settings for the
\n Hemopurifier sooner or later and
\n could enhance the scalability and accessibility of therapy if
\n efficiently developed and validated.<\/strong>
\n <\/p>\n
\n
<\/p>\n
\n Subsequent to fiscal year-end, an interview revealed in IEEE Spectrum
\n that includes Aethlon’s Chief Medical Officer and a doctor concerned in
\n the therapy of an Ebola virus illness affected person with the Hemopurifier
\n through the 2014 outbreak highlighted the Firm’s expertise with
\n Ebola therapy efforts. In reference to renewed public well being
\n curiosity surrounding current Ebola outbreaks, we additionally confirmed the
\n continued availability of our FDA-authorized expanded entry
\n (compassionate use) protocol and shared the protocol in addition to previous
\n in vitro and in vivo knowledge with organizations concerned in international and
\n U.S. rising pathogen preparedness efforts, together with the World Well being
\n Group’s R&D Blueprint skilled panel and the Nationwide Rising
\n Particular Pathogen Coaching and Training Middle.
\n <\/p>\n
\n
<\/p>\n
\n Monetary Outcomes for the Fiscal Yr Ended March 31, 2026
\n <\/h2>\n
\n
<\/p>\n
\n As of March 31, 2026, the Firm had roughly $5.0 million in
\n money and money equivalents, offering sources to assist ongoing
\n medical and analysis actions.
\n <\/p>\n
\n
<\/p>\n
\n Subsequent to fiscal year-end, the Firm strengthened its stability
\n sheet by elevating roughly $1.85 million in web proceeds by way of
\n its at-the-market program.
\n <\/p>\n
\n
<\/p>\n
\n Consolidated working bills declined 21.9% year-over-year to
\n roughly $7.3 million, reflecting continued expense self-discipline and
\n operational effectivity whereas advancing the Firm’s medical and
\n analysis priorities in comparison with $9.3 million for the fiscal yr ended
\n March 31, 2025. The lower was primarily resulting from $1.1 million
\n discount in payroll and associated bills, a $500,000 discount in
\n normal and administrative bills and a $400,000 discount in
\n skilled charges.
\n <\/p>\n
\n
<\/p>\n
\n Per the discount in working bills, the working
\n loss for the fiscal yr decreased to roughly $7.3 million for
\n fiscal 2026 from $9.3 million within the prior fiscal yr.
\n <\/p>\n
\n
<\/p>\n
\n Different revenue was roughly $142,000 for the fiscal yr ended
\n March 31, 2026, primarily reflecting curiosity revenue earned on money
\n balances, in comparison with different expense of roughly $4 million within the
\n prior fiscal yr. The prior-year quantity included roughly $4.7
\n million of non-cash financing-related costs.
\n <\/p>\n
\n
<\/p>\n
\n Internet loss attributable to our widespread stockholders was $7.2 million for
\n the fiscal yr ended March 31, 2026, in comparison with web lack of $13.4
\n million for the fiscal yr ended March 31, 2025.
\n <\/p>\n
\n
<\/p>\nConvention Name<\/h2>\n
\n
<\/p>\n
\n Administration will host a convention name immediately, Wednesday, June 10,
\n 2026, at 4:30 p.m. ET to evaluation the Firm’s monetary outcomes and
\n current company developments. Following administration’s formal remarks,
\n there might be a question-and-answer session.
\n <\/p>\n
\n
<\/p>\n
\n events can register for the convention name by navigating
\n to
\n https:\/\/dpregister.com\/sreg\/10209612\/1042263e8ec<\/a>. Please be aware that registered contributors will obtain their dial-in
\n quantity upon registration.
\n <\/p>\n
\n
<\/p>\n
\n events with out web entry or unable to pre-register
\n could dial in by calling:
\n PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
\n PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
\n <\/p>\n
\n
<\/p>\n
\n All callers ought to ask for the Aethlon Medical, Inc. convention name.
\n <\/p>\n
\n
<\/p>\n
\n A replay of the decision might be obtainable roughly one hour after
\n the tip of the decision by way of July 10, 2026. The replay may be accessed
\n through Aethlon Medical’s web site or by dialing 1-855-669-9658 (USA or
\n Canada) or 1-412-317-0088 (worldwide) or Canada toll free at
\n 1-855-669-9658. The replay convention ID quantity is 7883435.
\n <\/p>\n
\n
<\/p>\nConcerning the Hemopurifier(R)<\/h2>\n
\n
<\/p>\n
\n The Aethlon Hemopurifier is an investigational medical gadget designed
\n to take away enveloped viruses and tumor-derived extracellular vesicles
\n (EVs) from circulation. It’s used extracorporeally with a blood pump
\n and combines plasma separation, measurement exclusion, and affinity binding
\n utilizing a plant lectin resin that targets mannose-rich surfaces discovered on
\n EVs and viruses. EVs launched by stable tumors are believed to play a
\n function in metastasis and the resistance to immunotherapies and
\n chemotherapy. Removing of enveloped viruses and extracellular vesicles
\n has been demonstrated in each in vitro research and human topics.
\n <\/p>\n
\n
<\/p>\n
\n The Hemopurifier holds a U.S. Meals and Drug Administration Breakthrough
\n Gadget Designation for:
\n <\/p>\n
\n
<\/p>\n
\n The therapy of people with superior or metastatic most cancers
\n unresponsive to or illiberal of standard-of-care remedy; and the
\n therapy of life-threatening viruses not addressed with authorized
\n therapies.
\n <\/p>\n
\n
<\/p>\n
\n Full information and financials from AEMD<\/a><\/strong>
\n <\/p>\n
\n
<\/p>\n
\n
\n Extra information on AEMD at Investorideas.com<\/a>
\n <\/strong>
\n <\/p>\n
\n
<\/p>\n
\n Get Information Alerts on Aethlon Medical<\/a>
\n <\/p>\n
\n
\n
\n
<\/p>\n
\n Analysis biotech shares at Investorideas.com:
\n https:\/\/www.investorideas.com\/Firms\/RenewableEnergy\/stock_list.asp<\/a>
\n <\/p>\n
\n
<\/p>\n
\n Join free inventory information alerts at Investorideas.com:
\n <\/p>\n
\n https:\/\/www.investorideas.com\/Assets\/E-newsletter.asp<\/a>
\n <\/p>\n
\n
\n
\n
<\/p>\n
\n About Investorideas.com – Huge Investing Concepts
\n <\/h3>\n
\n Investorideas.com<\/a>
\n is a trusted platform for retail buyers, serving as a hub for
\n revolutionary investing concepts for over 25 years. Recognized for its pioneering
\n protection of sectors like mining, cleantech, protection, and water shares,
\n the corporate and its executives have been featured in high-profile
\n media shops for its experience. Investorideas.com is at all times on the
\n forefront of funding traits, providing protection of numerous
\n industries corresponding to AI, mining, and tech. With a mission to empower
\n buyers, the corporate offers breaking information, sector-focused
\n articles, podcasts, and unique interviews with main specialists. In
\n addition, its award-winning branded content material, AI-driven brief movies,
\n and podcasts spotlight key investing insights and have outstanding
\n trade leaders.
\n <\/p>\n
\n
<\/p>\n
\n Investor Concepts digital promoting and visitor posts service:
\n https:\/\/www.investorideas.com\/Promote\/<\/a>
\n <\/p>\n
\n
<\/p>\n
\n Comply with us on X @investorideas @stocknewsbites
Comply with us on
\n Fb
\n https:\/\/www.fb.com\/Investorideas<\/a>
Comply with Investorideas and the Exploring Mining Podcast on YouTube
\n https:\/\/www.youtube.com\/c\/Investorideas<\/a>
\n <\/p>\n
\n
<\/p>\n
\n Buyers keep forward by signing up free of charge inventory information alerts at
\n Investorideas.com
\n <\/p>\n
\n
<\/p>\n
\n Be a part of our free Telegram neighborhood
\n https:\/\/t.me\/+o8DxSAgeNCk2ZGVh<\/a>
\n <\/p>\n
\n
<\/p>\n
Name 800 665 0411<\/p>\n
\n Aethlon Medical, Inc. (Nasdaq: AEMD) is a paid featured medical tech
\n inventory on Investorideas.com.
\n Extra disclosure<\/a>: Investorideas.com is a digital writer of third social gathering sourced information,
\n articles and fairness analysis in addition to creates unique content material,
\n together with video, interviews and articles. Unique content material created by
\n investorideas is protected by copyright legal guidelines aside from syndication
\n rights. Our website doesn’t make suggestions for purchases or sale of
\n shares, companies or merchandise. Nothing on our websites ought to be construed
\n as a suggestion or solicitation to purchase or promote merchandise or securities. All
\n investing entails threat and potential losses. This website is at present
\n compensated for information publication and distribution, social media and
\n advertising, content material creation and extra.
\n Extra disclosure<\/a>: Contact administration and IR of every firm instantly concerning particular
\n questions.
\n <\/p>\n\n","protected":false},"excerpt":{"rendered":"